Literature DB >> 8665056

Serum indicators of free radical activity in idiopathic pulmonary fibrosis.

C I Jack1, M J Jackson, I D Johnston, C R Hind.   

Abstract

Serum levels of free radical activity were measured in 37 patients with idiopathic pulmonary fibrosis (IPF) and 16 control subjects. Three assays used were (1) simultaneously measured levels of the 9,11-diene conjugate of linoleic acid and 9,12-linoleic acid expressed as a percent molar ratio (%MR), a measure of free-radical-mediated lipid peroxidation; (2) thiobarbituric acid reactive substances (TBARS), one of which is malondialdehyde; (3) desferrioxamine-chelatable iron assay, a measure of the potential iron available to catalyze free radical generation. Mean %MR, TBARS and desferrioxamine-chelatable iron were all elevated initially in patients with IPF compared with control subjects (%MR, p < 0.0001; TBARS, p = 0.0013; desferrioxamine-chelatable iron, p = 0.0029). Furthermore, the serum %MR was higher in a subset of patients with clinically worsening IPF than in those patients with clinically stable disease (p = 0.002). Treatment did not appear to affect the three different serum indicators of free radical activity. Thus, lipid peroxidation appears to be increased in patients with IPF and is associated with an increase in desferrioxamine-chelatable iron levels. Serum % MR levels appeared to correlate with clinical disease activity, and they may have a role in monitoring disease activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665056     DOI: 10.1164/ajrccm.153.6.8665056

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  6 in total

Review 1.  Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.

Authors:  Bashar S Staitieh; Elisabetta A Renzoni; Srihari Veeraraghavan
Journal:  Ann Med       Date:  2015-01-22       Impact factor: 4.709

2.  Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis.

Authors:  Amira Ismail Mostafa; Ayman Elsayed Salem; Heba Allah Moussa Ahmed; Aml Ibrahim Bayoumi; Radwa M Abdel Halim; Rasha M Abdel Samie
Journal:  Tuberc Respir Dis (Seoul)       Date:  2021-04-06

Review 3.  Novel therapeutic approaches for pulmonary fibrosis.

Authors:  Arnab Datta; Chris J Scotton; Rachel C Chambers
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

4.  Iron metabolism regulation of epithelial-mesenchymal transition in idiopathic pulmonary fibrosis.

Authors:  Yi Han; Ling Ye; Fang Du; Maosong Ye; Chun Li; Xiaodan Zhu; Qin Wang; Hongni Jiang; Zilong Liu; Jiefei Ma; Jian Zhou; Chunxue Bai; Yuanlin Song; Jie Liu
Journal:  Ann Transl Med       Date:  2021-12

Review 5.  Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis.

Authors:  Cristina Estornut; Javier Milara; María Amparo Bayarri; Nada Belhadj; Julio Cortijo
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

Review 6.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.